Evidence map›Paper›PMID 18492603›Full record

ReviewCancer letters2008

Multi-targeted therapy of cancer by genistein.

Sanjeev Banerjee, Yiwei Li, Zhiwei Wang, Fazlul H Sarkar

Open access · greenAbstract readReview
In one paragraph

Review in Cancer letters, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 1 pooled it
24.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 1 synthesis or guideline pooled it, 609 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.International journal of molecular sciences · 2025
    Review
  20. CORN 2.0 - Condition Orientated Regulatory Networks 2.0.Computational and structural biotechnology journal · 2025
    Article

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sanjeev BanerjeeDepartment of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, 740 Hudson Webber Cancer Research Center, 110 E Warren, Detroit, MI 48201, USA.
Yiwei Li
Zhiwei Wang
Fazlul H Sarkar
The Barbara Ann Karmanos Cancer Institute · US

Funding

SPORE in Pancreatic CancerP20CA101936 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABBRUZZESE, JAMES L. · 2003 to 2009
$5.4M
Novel Targets of Indoles in Prostate CancerR01CA108535 · NCI · WAYNE STATE UNIVERSITY · PI SARKAR, FAZLUL H. · 2004 to 2014
$2.7M
Molecular Mechanism of Genistein (Isoflavone) in Prostate CancerR01CA083695 · NCI · WAYNE STATE UNIVERSITY · PI SARKAR, FAZLUL H. · 2001 to 2011
$2.3M
Targeting Akt/NF-kappa beta for Pancreatic Cancer TherapyR01CA101870 · NCI · WAYNE STATE UNIVERSITY · PI SARKAR, FAZLUL H. · 2003 to 2007
$1.6M
NCI NIH HHS 5P20-CA101936NCI NIH HHS 5R01CA083695NCI NIH HHS 5R01CA101870NCI NIH HHS 5R01CA108535NCI NIH HHS P20 CA101936NCI NIH HHS R01 CA083695NCI NIH HHS R01 CA101870NCI NIH HHS R01 CA108535
6 · The paper itself

Abstract

Soy isoflavones have been identified as dietary components having an important role in reducing the incidence of breast and prostate cancers in Asian countries. Genistein, the predominant isoflavone found in soy products, has been shown to inhibit the carcinogenesis in animal models. There is a growing body of experimental evidence showing that the inhibition of human cancer cell growth by genistein is mediated via the modulation of genes that are related to the control of cell cycle and apoptosis. It has been shown that genistein inhibits the activation of NF-kappaB and Akt signaling pathways, both of which are known to maintain a homeostatic balance between cell survival and apoptosis. Moreover, genistein antagonizes estrogen- and androgen-mediated signaling pathways in the processes of carcinogenesis. Furthermore, genistein has been found to have antioxidant properties, and shown to be a potent inhibitor of angiogenesis and metastasis. Taken together, both in vivo and in vitro studies have clearly shown that genistein, one of the major soy isoflavones is a promising agent for cancer chemoprevention and further suggest that it could be an adjunct to cancer therapy by virtue of its effects on reversing radioresistance and chemoresistance. In this review, we attempt to provide evidence for these preventive and therapeutic effects of genistein in a succinct manner highlighting comprehensive state-of-the-art knowledge regarding its multi-targeted biological and molecular effects in cancer cells.

Indexed as

Angiogenesis InhibitorsAnimalsAntioxidantsApoptosisCell CycleClinical Trials as TopicGenisteinHumansMaleMAP Kinase Signaling SystemNeoplasm MetastasisNeoplasmsNF-kappa BProstate-Specific AntigenProstatic NeoplasmsReceptors, AndrogenAngiogenesis InhibitorsAntioxidantsGenisteinNF-kappa BProstate-Specific AntigenReceptors, Androgen

Identifiers

PMID18492603
PMCPMC2575691
OpenAlexW2082942776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.